Blood-based testing compared with tissue testing for EGFR activating mutations had a positive percent agreement of 74.5% and a negative percent agreement of 90.5%, with a 78% overall percentage agreement between matched plasma and tumor tissue samples. This evidence concerns the gene EGFR and neoplasm.